{"entity":{"id":"nct05265091","kind":"trial","name":"A Study of KL590586 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of KL590586 Capsule in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of KL590586 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05265091 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 414 participants enrolled, started 2021-09-15 and due to reach its primary completion in 2026-12-31. Interventions recorded: KL590586 Capsule.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05265091","url":"https://clinicaltrials.gov/study/NCT05265091"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05265091","phase":"1/2","setting":"An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":414,"outcomes":[]},"route":"/trials/nct05265091/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}